Novel immunosuppressive strategies for bone marrow failure syndromes: A focus on Alemtuzumab

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 536-543

  Selleri, C ^a   Serio, B ^a,b   Risitano, A M ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Alemtuzumab; Aplastic anemia; Bone marrow failure

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A;

APLASTIC ANEMIA; BONE MARROW DEPRESSION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELODYSPLASTIC SYNDROMES;

EID: 79959418648     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795843329     Document Type: Review

References (82)

1. Young, N.; and Maciejewski, J.P. Aplastic Anemia. In: Hoffman R, Benz EJJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, ed. Hematology (Basic Principles and Practice). Philadelphia, Churchill Livingstone; 2000: 297-330.
2. Young, N.S. Acquired aplastic anemia. Ann. Intern. Med., 2002, 136,534-546.
3. Young, N.S.; and Maciejewski, J. The pathophysiology of acquired aplastic anemia. N. Engl. J. Med., 1997, 336, 1365-1372.
4. Risitano, A.M. Immunosuppressive Therapies in The Management of Immune-Mediated Marrow Failures in Adults: Where We Stand and Where We Are Going. Br. J. Haematol., 2010, 152, 127-40.
5. Maciejewski, J.P.; Anderson, S.; Katevas, P.; Young, N.S. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br. J. Haematol., 1994, 87, 227-234.
6. Maciejewski, J.P.; Selleri, C.; Sato, T.; Anderson, S.; Young, N.S. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood, 1996, 88, 1983-1991.
7. Maciejewski, J.P.; Kim, S.; Sloand, E.; Selleri, C.; Young, N.S. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am. J. Hematol., 2000, 65, 123-131.
8. Zeng, W.; Chen, G.; Kajigaya, S.; Nunez, O.; Charrow, A.; Billings, E.M.; Young, N.S. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood, 2004, 103, 325-332.
9. Kagan, W.A.; Ascensão, J.A.; Pahwa, R.N.; Hansen, J.A.; Goldstein, G.; Valera, E.B.; Incefy, G.S.; Moore, M.A.; Good, R.A. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc. Natl. Acad. Sci. U S A, 1976, 73, 2890-2894.
10. Zoumbos, N.; Gascon, P.; Trost, S.; Djeu, J.; Young, N. Circulating activated suppressor T lymphocytes in aplastic anemia. N. Engl. J. Med., 1985, 312, 257-265.
11. Maciejewski, J.P.; Selleri, C.; Sato, T.; Anderson, S.; Young, N. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br. J. Haematol., 1995, 91, 245-252.
12. Sato, T.; Selleri, C.; Anderson, S.; Young, N.S.; Maciejewski, J.P. Expression and modulation of cellular receptors for interferongamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br. J. Haematol., 1997, 97, 356-365.
13. Maciejewski, J.; Selleri, C.; Anderson, S.; Young, N.S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokinemediated hematopoietic suppression in vitro. Blood, 1995, 85, 3183-3190.
14. Selleri, C.; Maciejewski, J.P.; Sato, T.; Young, N.S. Interferongamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood, 1996, 87, 4149-4157.
15. Dufour, C.; Corcione, A.; Svahn, J.; Haupt, R.; Battilana, N.; Pistoia, V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br. J. Haematol., 2001, 115, 1023-1031.
16. Sloand, E.; Maciejewski, J.P.; Tisdale, J.; Follman, D.; Young, N.S. Intracellular Interferon-γ (IFN-γ) in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood, 2002, 100, 3129-3135.
17. Dufour, C.; Ferretti, E.; Bagnasco, F.; Burlando, O.; Lanciotti, M.; Ramenghi, U.; Saracco, P.; Van Lint, M.T.; Longoni, D.; Torelli, G.F.; Pillon, M.; Locasciulli, A.; Misuraca, A.; La Spina, M.; Bacigalupo, A.; Pistoia, V.; Corcione, A.; Svahn, J.; Marrow Failure Study Group of the AIEOP. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia. Haematologica, 2009, 94, 1743-1747.
18. Zeng, W.; Maciejewski, J.P.; Chen, G.; Young, N.S. Limited heterogeneity of T-cell receptor VB usage in aplastic anemia. J. Clin. Invest., 2001, 108, 765-773.
19. Kook, H.; Risitano, A.M.; Zeng, W.; Wlodarski, M.; Lottemann, C.; Nakamura, R.; Barrett, J.; Young, N.S.; Maciejewski, J.P. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood, 2002, 99, 3668-3675.
20. Risitano, A.M.; Kook, H.; Zeng, W.; Chen, G.; Young, N.S.; Maciejewski, J.P. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by Vβ CDR3 spectratyping and flow cytometry. Blood, 2002, 100, 178-183.
21. Nakao, S.; Takami, A.; Takamatsu, H, Zeng, W.; Sugimori, N.; Yamazaki, H.; Miura, Y.; Ueda, M.; Shiobara, S.; Yoshioka, T.; Kaneshige, T.; Yasukawa, M.; Matsuda, T. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood, 1997, 89, 3691-3699.
22. Risitano, A.M.; Maciejewski, J.P.; Green, S.; Plasilova, M.; Zeng, W., Young, N.S. In vivo dominant immune responses in aplastic anemia patients: molecular tracking of putatively pathogenic T cells by TCRβ-CDR3 sequencing. Lancet, 2004, 364, 353-363.
23. Hirano, N.; Butler, M.O.; Von Bergwelt-Baildon, M.S.; Maecker, B.; Schultze, J.L.; O'Connor, K.C.; Schur, P.H.; Kojima, S.; Guinan, E.C.; Nadler, L.M. Autoantibodies frequently detected in patients with aplastic anemia. Blood, 2003, 102, 4567-75.
24. Feng, X.; Chuhjo, T.; Sugimori, C.; Kotani, T.; Lu, X.; Takami, A.; Takamatsu, H.; Yamazaki, H.; Nakao, S. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood, 2004, 104, 2425-2431.
25. Takamatsu, H.; Feng, X.; Chuhjo, T.; Lu, X.; Sugimori, C.; Okawa, K.; Yamamoto, M.; Iseki, S.; Nakao, S. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood, 2007, 109, 2514-2520.
26. Mathé, G.; and Schwarzenberg, L. Treatment of bone marrow aplasia by mismatched bone marrow transplantation after conditioning with antilymphocyte globulin--long-term results. Transplant Proceedings, 1976, 8, 595-602.
27. Speck, B.; Gluckman, E.; Haak, H.L.; van Rood, J.J. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet, 1977, 2, 1145-1148.
28. Champlin, R.; Ho, W.; Gale, R.P. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N. Engl. J. Med., 1983, 308, 113-118.
29. Young, N.; Griffith, P.; Brittain, E.; Elfenbein, G.; Gardner, F.; Huang, A.; Harmon, D.; Hewlett, J.; Fay, J.; Mangan, K.; Morrison, F.; Sensenbrenner, S.; Shadduck, R.; Wang, W.; Zaroulis, C.; Zuckerman, C. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood, 1988, 72, 1861-1869.
30. de Planque, M.M.; Bacigalupo, A.; Würsch, A.; Hows, J.M.; Devergie, A.; Frickhofen, N.; Brand, A.; Nissen, C. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br. J. Haematol., 1989, 73, 121-126.
31. Frickhofen, N.; Kaltwasser, J.P.; Schrezenmeier, H.; Raghavachar, A.; Vogt, H.G.; Herrmann, F.; Freund, M.; Meusers, P.; Salama, A.; Heimpel, H. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N. Engl. J. Med., 1991, 324, 1297-1304.
32. Frickhofen, N.; Heimpel, H.; Kaltwasser, J.P.; Schrezenmeier, H.; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood, 2003, 101, 1236-1242.
33. Rosenfeld, S.; Follmann, D.; Nunez, O.; Young, N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA, 2003, 289, 1130-1135.
34. Young, N.S.; Calado, R.T.; Scheinberg, P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood, 2006, 108, 2509-2519.
35. Marsh, J. Making therapeutic decisions in adults with aplastic anemia. Hematology American Society Hematology Education Program, 2006, 78-85.
36. Bacigalupo, A. Aplastic anemia: pathogenesis and treatment. Hematology American Society of Hematology Education Program, 2007, 23-28.
37. Scheinberg, P.; Wu, C.O.; Scheinberg, P.; Weinstein, B.; Nunez, O.; Sloand, E.M.; Young, N.S. A Randomized Trial of Horse Versus Rabbit Antithymocyte Globulin In Severe Acquired Aplastic Anemia. Blood, 2010, 116, LBA-4(a).
38. Bacigalupo, A.; Bruno, B.; Saracco, P.; Di Bona, E.; Locasciulli, A.; Locatelli, F.; Gabbas, A.; Dufour, C.; Arcese, W., Testi, G.; Broccia, G.; Carotenuto, M.; Coser, P.; Barbui, T.; Leoni, P.; Ferster, A. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood, 2000, 95, 1931-1934.
39. Tichelli, A.; Schrezenmeier, H.; Socié, G.; Marsh, J.; Bacigalupo, A.; Dührsen, U.; Franzke, A.; Hallek, M.; Thiel, E.; Wilhelm, M.; Höchsmann, B.; Barrois, A.; Champion, K.; Passweg, J.R. A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the EBMT. Blood, 2011, Jan 13 [Epub ahead of print]
40. Maciejewski, J.P.; and Risitano, A.M. Aplastic anemia: management of adult patients. Hematology American Society of Hematology Education Program, 2005, 110-117.
41. Tichelli, A.; Passweg, J.; Nissen, C.; Bargetzi, M.; Hoffmann, T.; Wodnar-Filipowicz, A.; Signer, E.; Speck, B.; Gratwohl, A. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br. J. Haematol., 1998, 100, 393-400.
42. Di Bona, E.; Rodeghiero, F.; Bruno, B.; Gabbas, A.; Foa, P.; Locasciulli, A.; Rosanelli, C.; Camba, L.; Saracco, P.; Lippi, A.; Iori, A.P.; Porta, F.; De Rossi, G.; Comotti, B.; Iacopino, P.; Dufour, C.; Bacigalupo, A. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br. J. Haematol., 1999, 107, 330-334.
43. Scheinberg, P.; Nunez, O.; Young, N.S. Re-treatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br. J. Haematol., 2006, 133, 622-627.
44. Dumont, F.J. Alemtuzumab (Millennium/ILEX). Curr. Opin. Investig. Drugs, 2001, 2, 139-160.
45. Hale, G.; Rebello, P.; Brettman, L.R.; Fegan, C.; Kennedy, B.; Kimby, E.; Leach, M.; Lundin, J.; Mellstedt, H.; Moreton, P.; Rawstron, A.C.; Waldmann, H.; Osterborg, A.; Hillmen, P. Blood concentrations of alemtuzumab and antiglobulins responses in patients with chronic lymphocytic leucemia following intravenous or subcutaneous route of administration. Blood, 2004, 104, 948-955.
46. Kottaridis, P.D.; Milligan, D.W.; Chopra, R.; Chakraverty, R.K.; Chakrabarti, S.; Robinson, S.; Peggs, K.; Verfuerth, S.; Pettengell, R.; Marsh, J.C.; Schey, S.; Mahendra, P.; Morgan, G.J.; Hale, G.; Waldmann, H.; de Elvira, M.C.; Williams, C.D.; Devereux, S.; Linch, D.C.; Goldstone, A.H.; Mackinnon, S. In vivo Campath-1H prevents graft-versus-host disease following non myeloablative stem cell transplantation. Blood, 2000, 96, 2419-2425.
47. Chakraverty, R.; Peggs, K.; Chopra, R.; Milligan, D.W.; Kottaridis, P.D.; Verfuerth, S.; Geary, J.; Thuraisundaram, D.; Branson, K.; Chakrabarti, S.; Mahendra, P.; Craddock, C.; Parker, A.; Hunter, A.; Hale, G-; Waldmann, H.; Williams, C.D.; Yong, K.; Linch, D.C.; Goldstone, A.H.;Mackinnon, S. Limiting transplantationrelated mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 2002, 99, 1071-1078.
48. Gupta, V.; Ball, S.E.; Yi, Q.L.; Sage, D.; McCann, S.R.; Lawler, M.; Ortin, M.; Freires, M.; Hale, G.; Waldmann, H.; Gordon-Smith, E.C.; Marsh, J.C. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol. Blood Marrow Transpl., 2004, 10, 867-876.
49. Gupta, V.; Ball, S.E.; Sage, D.; Ortin, M.; Freires, M.; Gordon-Smith, E.C.; Marsh, J.C. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transpl., 2005, 35, 467-471.
50. Morris, E.C.; Rebello, P.; Thomson, K.J.; Peggs, K.S.; Kyriakou, C.; Goldstone, A.H.; Mackinnon, S.; Hale, G. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantation: relevance for early adoptive immunotherapy and infectious complications. Blood, 2003, 102, 404-406.
51. Willis, F.; Marsh, J.C.W.; Bevan, D.H.; Killick, S.B.; Lucas, G.; Griffiths, R.; Ouwehand, W.; Hale, G.; Waldmann, H.; Gordon-Smith, E.C. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol., 2001, 114, 891-898.
52. Marsh, J.C.; and Gordon-Smith, E.C. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy, 2001, 3, 189-195.
53. Elter, T.; Vehreschild, J.J.; Gribben, J.; Cornely, O.A.; Engert, A.; Hallek, M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann, Hematol., 2008, 88, 121-132.
54. Kim, H.; Min, Y.J.; Baek, J.H.; Shin, S.J.; Lee, E.H.; Noh, E.K.; Kim, M.Y.; Park, J.H. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk. Res., 2009, 33, 222-231.
55. Risitano, A.M.; Selleri, C.; Serio, B.; Torelli, G.F.; Kulagin, A.; Maury, S.; Halter, J.; Gupta, V.; Bacigalupo, A.; Sociè, G.; Tichelli, A.; Schrezenmeier, H.; Marsh, J.; Passweg, J.; Rotoli, B.; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br. J. Haematol., 2010, 148, 791-796.
56. Risitano, A.M.; Serio, B.; Selleri, C.; Rotoli, B. Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Ann. Hematol., 2009, 88, 1261-1262.
57. Gibbs, S.D.; Westerman, D.A.; McCormack, C.; Seymour, J.F.; Miles Prince, H. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br. J. Haematol., 2005, 130, 87-91
58. Taylor, V.C.; Sims, M.; Brett, S.; Field, M.C. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism. Biochem. J., 1997, 322, 919-925.
59. Rawstron, A.C.; Rollinson, S.J.; Richards, S. Short, M.A.; English, A.; Morgan, G.J.; Hale, G.; Hillmen P. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br. J. Haematol., 1999, 107, 148-153.
60. Gómez-Almaguer, D.; Jaime-Pérez, J.C.; Garza-Rodríguez, V.; Chapa-Rodríguez, A.; Tarín-Arzaga, L.; Herrera-Garza, J.L.; Ruiz-Argüelles, G.J.; López-Otero, A.; González-Llano, O.; Rodríguez-Romo, L. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann. Hematol., 2010, 89, 299-303.
61. Sawada, K.; Fujishima, N.; Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br. J. Haematol., 2008, 142, 505-514.
62. Au, W.Y.; Lam, C.C.; Chim, C.S.; Pang, A.W.; Kwong, Y.L. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk. Res., 2005, 29, 1213-1215.
63. Ru, X.; Liebman, H.A. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br. J. Haematol., 2003, 123, 278-281.
64. Schützinger, C.; Gaiger, A.; Thalhammer, R.; Vesely, M.; Fritsche- Polanz, R.; Schwarzinger, I.; Ohler, L.; Simonitsch-Klupp, I.; Reinhard, F.; Jäger, U. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia, 2005, 19, 2005-2008.
65. Alvares, C.L.; Svasti-Salee, D.; Rowley, M.; Gordon-Smith, E.C.; Marsh, J.C. Remission induced by Campath-1H for thymomaassociated agranulocytosis. Ann. Hematol., 2004, 83, 398-400.
66. Killick, S.B.; Marsh, J.C.; Hale, G.; Waldmann, H.; Kelly, S.J.; Gordon-Smith, E.C. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br. J. Haematol., 1997, 97, 306-308.
67. Osuji, N.; Del Giudice, I.; Matutes, E.; Morilla, A.; Owusu-Ankomah, K.; Morilla, R.; Dunlop, A.; Catovksy, D. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Leuk. Lymphoma, 2005, 46, 723-727.
68. Osuji, N.; Matutes, E.; Tjonnfjord, G.; Grech, H.; Del Giudice, I.; Wotherspoon, A.; Swansbury, J.G.; Catovsky, D. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer, 2006, 107, 570-578.
69. Aribi, A.; Huh, Y.; Keating, M.; O'Brien, S.; Ferrajoli, A.; Faderl, S.; Wierda, W.; Kantarjian, H.; Ravandi, F. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk. Res., 2007, 31, 939-945.
70. Fortune, A.F.; Kelly, K.; Sargent, J.; O'Brien, D.; Quinn, F.; Chadwick, N.; Flynn, C.; Conneally, E.; Browne, P.; Crotty, G.M.; Thornton, P.; Vandenberghe, E. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk. Lymphoma, 2010, 51, 839-845.
71. Rosenblum, M.D.; LaBelle, J.L.; Chang, C.C.; Margolis, D.A.; Schauer, D.W.; Vesole, D.H. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood, 2004, 103, 1969-1971.
72. Mohan, S.R.; Clemente, M.J.; Afable, M.; Cazzolli, H.N.; Bejanyan, N.; Wlodarski, M.W.; Lichtin, A.E.; Maciejewski, J.P. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica, 2009, 94, 1407-1414.
73. Barrett, A.J.; and Sloand, E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica, 2009, 94, 449-451.
74. Kochenderfer, J.N.; Kobayashi, S.; Wieder, E.D.; Su, C.; Molldrem, J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood, 2002, 100, 3639-3645.
75. Selleri, C.; Maciejewski, J.P.; Catalano, L.; Ricci, P.; Andretta, C.; Luciano, L.; Rotoli, B. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer, 2002, 95, 1911-1922.
76. Catalano, L.; Selleri, C.; Califano, C.; Luciano, L.; Volpicelli, M.; Rocco, S.; Varriale, G.; Ricci, P.; Rotoli, B. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica,. 2000, 85, 133-138.
77. Shimamoto, T.; Tohyama, K.; Okamoto, T.; Uchiyama, T.; Mori, H.; Tomonaga, M.; Asano, Y.; Niho, Y.; Teramura, M.; Mizoguchi, H.; Omine, M.; Ohyashiki, K. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk. Res., 2003, 27, 783-788.
78. Jonásova, A.; Neuwirtová, R.; Cermák, J.; Vozobulová, V.; Mociková, K.; Sisková, M.; Hochová, I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol., 1998, 100, 304-309.
79. Saunthararajah, Y.; Nakamura, R.; Nam, J.M.; Robyn, J.; Loberiza, F.; Maciejewski, J.P.; Simonis, T.; Molldrem, J.; Young, N.S.; Barrett, A.J. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 2002, 100, 1570-1574.
80. Lim, Z.Y.; Killick, S.; Germing, U.; Cavenagh, J.; Culligan, D.; Bacigalupo, A.; Marsh, J.; Mufti, G.J. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia, 2007, 21, 1436-1441.
81. Saunthararajah, Y.; Nakamura, R.; Wesley, R.; Wang, Q.J.; Barrett, A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood, 2003, 102, 3025-3027.
82. Sloand, E.M.; Olnes, M.J.; Shenoy, A.; Weinstein, B.; Boss, C.; Loeliger, K.; Wu, C.O.; More, K.; Barrett, A.J.; Scheinberg, P.; Young, N.S. Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. J. Clin. Oncol., 2010, 28, 5166-5173.